TCG Crossover Management, LLC Q4 2021 Filing
Filed February 18, 2022
Portfolio Value
$213.6B
Holdings
15
Report Date
Q4 2021
Filing Type
13F-HR
All Holdings (15 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | OPHTEURIveric Bio, Inc. | 1,741,228 | $29.1B | 13.63% | |
| 2 | VRDNViridian Therapeutics Inc | 1,314,000 | $26.0B | 12.16% | |
| 3 | COGTCogent Biosciences, Inc. | 2,750,037 | $23.6B | 11.05% | |
| 4 | CBAYUSDCYMABAY THERAPEUTICS, INC. | 5,905,400 | $20.0B | 9.35% | |
| 5 | NVLSEURAlpine Immune Sciences, Inc. | 1,170,212 | $16.2B | 7.59% | |
| 6 | ACRSAclaris Therapeuitics, Inc. | 1,082,213 | $15.7B | 7.37% | |
| 7 | 290ACHINOOK THERAPEUTICS, INC. | 882,353 | $14.4B | 6.74% | |
| 8 | TYRATyra Biosciences, Inc. | 850,450 | $12.0B | 5.60% | |
| 9 | TRDAEntrada Therapeutics, Inc. | 663,694 | $11.4B | 5.32% | |
| 10 | AVTEAerovate Therapeutics, Inc. | 853,330 | $10.1B | 4.71% | |
| 11 | —Magenta Therapeutics, Inc. | 2,222,222 | $9.8B | 4.61% | |
| 12 | —Akouos, Inc. | 1,045,215 | $8.9B | 4.16% | |
| 13 | MRUSMerus N.V. | 225,000 | $7.2B | 3.35% | |
| 14 | ZLABZai Lab Limited | 95,000 | $6.0B | 2.80% | |
| 15 | —Elevation Oncology, Inc. | 555,000 | $3.3B | 1.56% |